Peretto Giovanni, Sala Simone, De Luca Giacomo, Marcolongo Renzo, Campochiaro Corrado, Sartorelli Silvia, Tresoldi Moreno, Foppoli Luca, Palmisano Anna, Esposito Antonio, De Cobelli Francesco, Rizzo Stefania, Thiene Gaetano, Basso Cristina, Dagna Lorenzo, Caforio Alida Linda Patrizia, Della Bella Paolo
Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, Milan, Italy; San Raffaele Vita-Salute University, Milan, Italy.
Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
JACC Clin Electrophysiol. 2020 Oct;6(10):1221-1234. doi: 10.1016/j.jacep.2020.05.013. Epub 2020 Jun 24.
This study sought to investigate the effects of immunosuppression on arrhythmic myocarditis.
The effects of immunosuppressive therapy (IST) on ventricular arrhythmia (VA) have not been reported in patients with immune-mediated biopsy-proven myocarditis. Furthermore, myocarditis arrhythmic risk is still unpredictable.
We enrolled 255 patients with biopsy-proven virus-negative myocarditis and VA (major: ventricular fibrillation, ventricular tachycardia; minor: nonsustained ventricular tachycardia, Lown grade ≥2 premature ventral complexes) at presentation. Serum cardiac autoantibodies (antiheart antibodies, anti-intercalated disk autoantibodies [AIDA]) were detected by a standardized indirect immunofluorescence technique. Whenever accepted and noncontraindicated, IST was started. Control individuals (IST) were chosen after 1:1 matching to IST patients by age, sex, ethnicity, left ventricular ejection fraction, VA type, and treatment.
A total of 58 matched patient couples (age 42 ± 13 years; 67% male) were analyzed in the main study cohort. IST duration was 12 ± 1 months. By the 24-month prospective follow-up, major VA occurred in 6 IST versus 10 IST patients (p = 0.42), with no episodes following IST termination. As compared to IST patients, IST patients showed a significant reduction in minor VA burden, as well as improvement in clinical, laboratory, and imaging findings (all p < 0.05). Major VA onset and positive AIDA status were independently associated with major VA at follow-up (hazard ratio [HR]: 14.2; 95% confidence interval [CI]: 2.9 to 68.7 and HR: 8.0; 95% CI: 2.6 to 25.2, respectively; both p < 0.001). Furthermore, in the whole study population (N = 255), IST was independently associated with protection from major VA (HR: 0.3; 95% CI: 0.2 to 0.7; p = 0.01) at 38 ± 21 months of follow-up.
In patients with immune-mediated virus-negative myocarditis presenting with VA, IST is associated with positive effects on minor VA and nonarrhythmic endpoints. Short-term effects are limited on major VA, which were independently associated with major VA onset and positive AIDA.
本研究旨在探讨免疫抑制对心律失常性心肌炎的影响。
免疫介导的经活检证实的心肌炎患者中,免疫抑制治疗(IST)对室性心律失常(VA)的影响尚未见报道。此外,心肌炎的心律失常风险仍然无法预测。
我们纳入了255例经活检证实为病毒阴性的心肌炎且伴有VA(主要:心室颤动、室性心动过速;次要:非持续性室性心动过速、洛恩分级≥2级室性早搏)的患者。采用标准化间接免疫荧光技术检测血清心脏自身抗体(抗心脏抗体、抗闰盘自身抗体[AIDA])。一旦被接受且无禁忌证,即开始IST治疗。通过年龄、性别、种族、左心室射血分数、VA类型和治疗情况,按1:1配比选择IST患者作为对照个体。
在主要研究队列中,共分析了58对匹配的患者夫妇(年龄42±13岁;67%为男性)。IST持续时间为12±1个月。经过24个月的前瞻性随访,6例接受IST治疗的患者与10例未接受IST治疗的患者发生了主要VA(p=0.42),IST治疗终止后未再出现发作。与未接受IST治疗的患者相比,接受IST治疗的患者次要VA负担显著减轻,临床、实验室和影像学检查结果也有所改善(均p<0.05)。主要VA发作和AIDA阳性状态与随访时的主要VA独立相关(风险比[HR]:14.2;95%置信区间[CI]:2.9至68.7,以及HR:8.0;95%CI:2.6至25.2,p均<0.001)。此外,在整个研究人群(N=255)中,随访38±21个月时,IST与预防主要VA独立相关(HR:0.3;95%CI:0.2至0.7;p=0.01)。
在伴有VA的免疫介导的病毒阴性心肌炎患者中,IST对次要VA和非心律失常终点有积极影响。对主要VA的短期影响有限,主要VA与主要VA发作和AIDA阳性独立相关。